Today: 1 July 2026
Browse Category

Pharmaceutical Industry 18 January 2026 - 3 February 2026

AbbVie stock ticks up ahead of earnings after Rinvoq vitiligo filing—what investors watch next

AbbVie stock ticks up ahead of earnings after Rinvoq vitiligo filing—what investors watch next

New York, Feb 3, 2026, 15:46 ET — Regular session AbbVie shares climbed Tuesday afternoon, despite cautious trading ahead of the drugmaker’s quarterly earnings report set for Wednesday before the U.S. open. By 3:46 p.m. ET, the stock gained $1.91, roughly 0.8%, to $227.55, after hitting an intraday high of $228.66.
3 February 2026
···
Denali Therapeutics stock price rises as FDA freezes rival Regenxbio’s Hunter syndrome gene therapy trials

Denali Therapeutics stock price rises as FDA freezes rival Regenxbio’s Hunter syndrome gene therapy trials

New York, Jan 29, 2026, 15:20 EST — Regular session • Denali Therapeutics shares climbed in afternoon trading, gaining ground while the broader biotech sector remained flat.• Attention intensified following the FDA’s decision to halt Regenxbio’s rare-disease gene therapy trials.• Investors are now zeroed in on Denali’s FDA timeline for its Hunter syndrome treatment and the data update expected in early February.
29 January 2026
····
GSK stock in focus as EU expands Arexvy RSV vaccine approval to all adults 18+

GSK stock in focus as EU expands Arexvy RSV vaccine approval to all adults 18+

London, Jan 26, 2026, 07:59 GMT — Premarket GSK announced that the European Commission has greenlit its RSV vaccine Arexvy for adults 18 and older, expanding eligibility beyond those 60-plus and high-risk individuals aged 50 to 59. “This approval helps protect all adults aged 18 and older in Europe against RSV,” said Sanjay Gurunathan, GSK’s head of Vaccines and Infectious Diseases R&D. The approval applies across EU member states and countries in the European Economic Area. GSK pointed to an average of 158,000 RSV-related adult hospitalisations annually within the EU.
26 January 2026
··
1 2 3 4 5 … 9

Stock Market Today

  • Pacific Current Group Tells ASX About Progress on Buy-Back Plan
    June 30, 2026, 11:38 PM EDT. Pacific Current Group Ltd (ASX: PAC) gave an update to the Australian Securities Exchange (ASX) on its on-market share buy-back program. The company is buying back its shares on market. Pacific Current is aiming to boost shareholder value through capital management. The announcement may affect stock liquidity and price. Investors can watch ASX announcements for more detail on the buy-back.
Go toTop